Longevity: could the 150-year life become reality? 

Posted on August 12th, 2026

Longer human life spans driven by better medicine and public health has been one of the most important social and economic transformations of the past two hundred years. In the UK, life expectancy has more than doubled since the 19th century.

Similar patterns are evident across advanced economies, and global life expectancy has risen steadily over recent decades. 

This trend will continue, but how far, and how fast? There is broad agreement among institutions such as the OECD and World Health Organization that further gains in life expectancy are likely, driven by continued advances in medical science and healthier ageing. The scale and pace of future gains is, naturally, uncertain. 

Mainstream projections are relatively cautious, suggesting continued increases in life expectancy, but at a slower rate than in previous decades. That reflects both biological constraints and the growing burden of chronic disease. OECD analysis notes that gains in “healthy life expectancy” have lagged behind increases in overall lifespan, underlining the challenge of extending not just how long people live, but how long they live in good health. 

Some parts of the scientific community see much greater potential for further increases. Some researchers argue that advances in understanding the biology of ageing—particularly in areas such as cellular senescence, epigenetics and DNA repair—could enable far more substantial extensions of human life.

Journals including Nature have highlighted rapid progress in longevity science, including the development of therapies targeting the underlying mechanisms of ageing. Meanwhile, as our Future Britain series will explore in different pieces, we may get better at preventing and managing those life-limiting chronic conditions. 

Few would formally project lifespans of 150 years becoming commonplace, but the idea is increasingly discussed as a possibility rather than pure speculation. There is clearly scope for change in the consensus as scientific and commercial interest in extending lives is accelerating, supported by advances in biotechnology, data science and AI-driven drug discovery. 

For investors, the implications of significant further extensions in lifespan are wide and deep. Pension systems of all sorts – and not just the LGPS – must take careful account of lifespans – the longer people live; the longer providers pay pensions. Insurance markets and public finances are also highly sensitive to longevity assumptions. The Office for Budget Responsibility has identified longevity as a key driver of long-term fiscal sustainability; age-related public spending – mainly state pensions, healthcare and social care – is projected to rise from around 20% of GDP today to over 30% by the 2070s.  That has implications for debt issuance and other items of public spending, as well as the overall capacity of the state.  

Longer lives would also reshape labour markets and patterns of consumption. If individuals remain healthier for longer, working lives will extend significantly, altering savings behaviour and asset allocation over the life cycle. Demand for financial products designed to manage longevity risk—such as annuities, drawdown strategies and later-life insurance—would be likely to increase. 

The growth potential for sectors linked to longevity is considerable. Life sciences, diagnostics, preventative healthcare and age-related services could all see sustained demand growth. Institutional investors are already increasing their exposure to these themes, reflecting expectations of continued innovation and rising healthcare needs. 

Longer lifespans are clearly a positive thing, and foster investment opportunities.  However, it is also possible that access to life-extending technologies could be uneven, with the longest and healthiest lives disproportionately concentrated among wealthier populations.  If this trend widens existing inequalities and creating new sources of social and political tension, it will engender risks that investment managers must consider and mitigate. 

Will humans one day routinely live to 150?  The question is worth pondering.  It also points to more challenges for investors, about how far and how fast the longevity frontier can move—and how economies, institutions and investment strategies adapt as it does.

Back to all News & Insights